Pharma Focus Asia

Eli Lilly Invests US$9 billion to Expand Manufacturing Site in Indiana, USA

Introduction:

Eli Lilly invests US$9 million in the newest Indiana site to boost API production for tirzepatide and pipeline medicines in USA.

Features: 

This expansion will increase the capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection, allowing more adults with chronic conditions such as obesity and type 2 diabetes to benefit from these vital treatments.

The multi-site campus will produce cutting-edge medications, including Zepbound and Mounjaro, support pipeline growth, and utilise the latest technology and automation for optimal efficiency, safety, and quality control.

Significantly, this investment creates high-wage, advanced manufacturing, engineering, and science jobs.

As part of this additional investment, the Lebanon site expects to add 200 full-time jobs for highly skilled workers, including engineers, scientists, operating personnel, and lab technicians, resulting in an estimated 900 full-time employees when the facility is fully operational.

The site is anticipated to start manufacturing medicines in Lebanon toward the end of 2026, with operations scaling up through 2028.

Specifications:

Name    Eli Lilly
Type       New Construction
Budget  US$9 billion
Year        2028


 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference